By Fineline Cube 
China-based Sinovac Biotech Ltd (NASDAQ: SVA) announced that it has received marketing approvals from the regulatory body in Hong Kong for its trivalent and quadrivalent influenza virus split vaccines. This marks a significant milestone for the company’s vaccine portfolio in the region.
Vaccine Details
Sinovac’s influenza vaccines have been registered in nearly 20 countries across Southeast Asia, Central Asia, South America, and Africa. The approval in Hong Kong underscores the global recognition of Sinovac’s vaccine development capabilities.
Market Significance
These vaccines are currently the only domestically produced seasonal influenza vaccines approved in Hong Kong. This approval positions Sinovac to play a crucial role in addressing public health needs and expanding its market presence in the region.-Fineline Info & Tech